Compare Stocks: NVS, LLY, JNJ, and MRK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$270.69 +1.2%	$255.08	$173.33 ▼ $276.47	$651.25B	0.24	7.00 million shs	6.18 million shs
LLY Eli Lilly and Company	$1,257.26 +1.0%	$1,180.14	$694.23 ▼ $1,292.65	$1.18T	0.51	2.83 million shs	2.50 million shs
MRK Merck & Co., Inc.	$152.43 +2.3%	$128.09	$77.58 ▼ $154.49	$376.37B	0.19	10.03 million shs	15.96 million shs
NVS Novartis	$159.06 +1.8%	$154.35	$121.57 ▼ $170.46	$303.13B	0.45	1.57 million shs	1.18 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	0.00%	+3.94%	+4.38%	+15.35%	+51.57%
LLY Eli Lilly and Company	0.00%	+6.35%	+6.07%	+17.88%	+78.40%
MRK Merck & Co., Inc.	0.00%	+12.27%	+16.74%	+24.38%	+80.02%
NVS Novartis	0.00%	+5.32%	+1.75%	+4.55%	+25.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JNJ Johnson & Johnson	$270.69 +1.2%	$255.08	$173.33 ▼ $276.47	$651.25B	0.24	7.00 million shs	6.18 million shs
LLY Eli Lilly and Company	$1,257.26 +1.0%	$1,180.14	$694.23 ▼ $1,292.65	$1.18T	0.51	2.83 million shs	2.50 million shs
MRK Merck & Co., Inc.	$152.43 +2.3%	$128.09	$77.58 ▼ $154.49	$376.37B	0.19	10.03 million shs	15.96 million shs
NVS Novartis	$159.06 +1.8%	$154.35	$121.57 ▼ $170.46	$303.13B	0.45	1.57 million shs	1.18 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JNJ Johnson & Johnson	0.00%	+3.94%	+4.38%	+15.35%	+51.57%
LLY Eli Lilly and Company	0.00%	+6.35%	+6.07%	+17.88%	+78.40%
MRK Merck & Co., Inc.	0.00%	+12.27%	+16.74%	+24.38%	+80.02%
NVS Novartis	0.00%	+5.32%	+1.75%	+4.55%	+25.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JNJ Johnson & Johnson	2.80	Moderate Buy	$268.22	-0.91% Downside
LLY Eli Lilly and Company	2.83	Moderate Buy	$1,292.18	2.78% Upside
MRK Merck & Co., Inc.	2.65	Moderate Buy	$144.10	-5.46% Downside
NVS Novartis	2.31	Hold	$141.20	-11.23% Downside

Current Analyst Ratings Breakdown

Latest NVS, LLY, JNJ, and MRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	MRK Merck & Co., Inc.	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$140.00 ➝ $160.00
8/20/2026	MRK Merck & Co., Inc.	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$142.00 ➝ $170.00
8/20/2026	MRK Merck & Co., Inc.	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$145.00 ➝ $175.00
8/20/2026	MRK Merck & Co., Inc.	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$142.00 ➝ $150.00
8/20/2026	MRK Merck & Co., Inc.	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$116.00 ➝ $179.00
8/19/2026	MRK Merck & Co., Inc.	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2026	MRK Merck & Co., Inc.	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$143.00
8/11/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/11/2026	MRK Merck & Co., Inc.	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
8/11/2026	MRK Merck & Co., Inc.	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$130.00 ➝ $145.00
8/7/2026	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$1,376.00

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JNJ Johnson & Johnson	$94.19B	6.93	$14.14 per share	19.14	$35.26 per share	7.68
LLY Eli Lilly and Company	$65.18B	18.16	$25.18 per share	49.94	$35.99 per share	34.93
MRK Merck & Co., Inc.	$65.01B	5.78	$11.42 per share	13.35	$17.02 per share	8.96
NVS Novartis	$54.53B	5.57	$10.75 per share	14.79	$21.98 per share	7.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JNJ Johnson & Johnson	$26.80B	$8.63	31.37	21.15	2.58	21.48%	32.42%	13.35%	10/13/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$29.80	42.19	27.41	1.48	33.53%	97.83%	23.23%	10/29/2026 (Estimated)
MRK Merck & Co., Inc.	$18.25B	$1.25	121.94	15.78	6.58	4.77%	16.73%	6.13%	10/29/2026 (Estimated)
NVS Novartis	$13.98B	$6.63	23.99	16.21	2.72	23.29%	38.56%	14.47%	10/27/2026 (Estimated)

Latest NVS, LLY, JNJ, and MRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	LLY Eli Lilly and Company	$6.40	$8.38	+$1.98	$7.94	$20.82 billion	$22.97 billion
8/4/2026	Q2 2026	MRK Merck & Co., Inc.	-$0.26	-$0.13	+$0.13	-$0.54	$16.37 billion	$16.61 billion
7/21/2026	Q2 2026	NVS Novartis	$2.17	$2.41	+$0.24	$1.71	$14.07 billion	$14.41 billion
7/15/2026	Q2 2026	JNJ Johnson & Johnson	$2.84	$2.90	+$0.06	$2.27	$25.06 billion	$25.31 billion
6/30/2026	Q2 2026	NVS Novartis	N/A	$2.41	N/A	$1.71	N/A	$14.95 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
JNJ Johnson & Johnson	$5.36	1.98%	+5.25%	62.11%	64 Years
LLY Eli Lilly and Company	$6.92	0.55%	+15.18%	23.22%	11 Years
MRK Merck & Co., Inc.	$3.40	2.23%	+5.75%	272.00%	14 Years
NVS Novartis	$3.08	1.94%	+5.28%	46.46%	N/A

Latest NVS, LLY, JNJ, and MRK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2026	MRK Merck & Co., Inc.	quarterly	$0.85	2.61%	9/15/2026	9/15/2026	10/7/2026
6/22/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.59%	8/14/2026	8/14/2026	9/10/2026
7/15/2026	JNJ Johnson & Johnson	quarterly	$1.34	2.17%	8/25/2026	8/25/2026	9/8/2026
5/26/2026	MRK Merck & Co., Inc.	quarterly	$0.85	2.96%	6/15/2026	6/15/2026	7/8/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JNJ Johnson & Johnson	0.44	1.09	0.81
LLY Eli Lilly and Company	1.41	1.35	1.00
MRK Merck & Co., Inc.	1.22	1.32	1.10
NVS Novartis	0.89	0.86	0.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JNJ Johnson & Johnson	69.55%
LLY Eli Lilly and Company	82.53%
MRK Merck & Co., Inc.	76.07%
NVS Novartis	13.12%

Insider Ownership

Company	Insider Ownership
JNJ Johnson & Johnson	0.16%
LLY Eli Lilly and Company	0.14%
MRK Merck & Co., Inc.	0.17%
NVS Novartis	0.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JNJ Johnson & Johnson	138,200	2.41 billion	2.41 billion	Optionable
LLY Eli Lilly and Company	50,000	941.36 million	940.04 million	Optionable
MRK Merck & Co., Inc.	75,000	2.47 billion	2.46 billion	Optionable
NVS Novartis	75,267	1.91 billion	1.91 billion	Optionable

NVS, LLY, JNJ, and MRK Headlines

Recent News About These Companies

Novartis AG (NYSE:NVS) Receives Consensus Rating of "Hold" from Analysts

August 23 at 3:31 AM | americanbankingnews.com

Novartis AG NVS Stock Forecast & Price Target

August 20 at 8:18 AM | ca.finance.yahoo.com

Somerville Kurt F Invests $1.64 Million in Novartis AG $NVS

August 20 at 6:39 AM | marketbeat.com

Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play

August 19, 2026 | 247wallst.com

Enliven a new outperform at Barclays on potential of CML asset

August 18, 2026 | msn.com

This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem (NVS)

...

August 18, 2026 | marketbeat.com

Trust Co. of Vermont Purchases New Position in Novartis AG $NVS

August 18, 2026 | marketbeat.com

Novartis AG (NYSE:NVS) Receives Average Recommendation of "Hold" from Brokerages

August 18, 2026 | marketbeat.com

D.A. Davidson & CO. Lowers Position in Novartis AG $NVS

August 15, 2026 | marketbeat.com

Mirae Asset Global Investments Co. Ltd. Purchases 56,424 Shares of Novartis AG $NVS

August 14, 2026 | marketbeat.com

Boston Common Asset Management LLC Cuts Stock Position in Novartis AG $NVS

August 14, 2026 | marketbeat.com

Update: Market Chatter: Novartis Wins UK Court Challenge to Entresto Patent

August 13, 2026 | finance.yahoo.com

SOA Wealth Advisors LLC. Buys 14,416 Shares of Novartis AG $NVS

August 13, 2026 | marketbeat.com

Triasima Portfolio Management inc. Trims Holdings in Novartis AG $NVS

August 13, 2026 | marketbeat.com

Novartis AG $NVS Shares Purchased by Mission Wealth Management LP

August 13, 2026 | marketbeat.com

Erste Group Bank Cuts Earnings Estimates for Novartis

August 13, 2026 | americanbankingnews.com

Erste Group Bank Forecasts Weaker Earnings for Novartis

August 11, 2026 | marketbeat.com

Novartis AG Sponsored ADR

August 9, 2026 | cnn.com

The Manufacturers Life Insurance Company Sells 24,216 Shares of Novartis AG $NVS

August 6, 2026 | marketbeat.com

Research Analysts Offer Predictions for Novartis Q3 Earnings

August 5, 2026 | marketbeat.com

Segall Bryant & Hamill LLC Purchases Shares of 18,792 Novartis AG $NVS

August 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVS, LLY, JNJ, and MRK Company Descriptions

Johnson & Johnson NYSE:JNJ

$270.69 +3.32 (+1.24%)

As of 08/21/2026 03:58 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company NYSE:LLY

$1,257.26 +12.86 (+1.03%)

As of 08/21/2026 03:58 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. NYSE:MRK

$152.43 +3.44 (+2.31%)

As of 08/21/2026 03:58 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novartis NYSE:NVS

$159.06 +2.82 (+1.80%)

As of 08/21/2026 03:58 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVS, LLY, JNJ, and MRK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVS, LLY, JNJ, and MRK Earnings

Compare Dividends

Latest NVS, LLY, JNJ, and MRK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVS, LLY, JNJ, and MRK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NVS, LLY, JNJ, and MRK Company Descriptions

Johnson & Johnson NYSE:JNJ

Eli Lilly and Company NYSE:LLY

Merck & Co., Inc. NYSE:MRK

Novartis NYSE:NVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools